Loading…

The pharmacokinetics of ketoconazole in severely immunocompromised patients

Forty patients severely immunocompromised because of the nature of their underlying disease (marrow aplasia, acute leukaemia or solid tumour) and/or the treatment they were receiving, received ketoconazole 400 mg daily. All patients also received gut decontamination with non-absorbable antibiotics,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1982-12, Vol.10 (6), p.489-496
Main Authors: Hann, I. M., Prentice, H. G., Keaney, M., Corringham, R., Blacklock, H. A., Fox, J., Gascoigne, E., Van Custem, J.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Forty patients severely immunocompromised because of the nature of their underlying disease (marrow aplasia, acute leukaemia or solid tumour) and/or the treatment they were receiving, received ketoconazole 400 mg daily. All patients also received gut decontamination with non-absorbable antibiotics, skin antisepsis, sterile food and oral co-trimoxazole. Mean (±S.D.) peak serum ketoconazole levels of 5·14±1·4 mg/l occurred 3 h after drug intake. In patients not receiving an allogeneic bone marrow transplant (BMT), the mean serum level at 2 h post-dose remained in the range of 3 to 5 mg/l during prolonged therapy. In contrast, serum ketoconazole levels in allogeneic BMT patients declined during continued treatment. In addition, the incidence of fungal infections was significantly higher in allogeneic-BMT patients than in the other group (P
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/10.6.489